Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Transcode Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 13 | 7 | −6 |
| Shares | 643.4K | 417.1K | −226.4K (−35.2%) |
| Value | $105.4K | $284.1K | +$178.7K (+169.5%) |
New holders (3)
Institutions that held Transcode Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 334,823 | $228.7K | 1.50% |
| Virtu Financial LLC | 55,329 | $37.0K | 0.00% |
| Two Sigma Securities, LLC | 21,975 | $15.0K | 0.00% |
Sold out (9)
Institutions that held Transcode Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Citadel Advisors LLC | 281,908 | $46.5K |
| Renaissance Technologies LLC | 187,400 | $31.0K |
| Geode Capital Management, LLC | 52,232 | $8.61K |
| Captrust Financial Advisors | 50,000 | $8.24K |
| HRT Financial LP | 34,966 | $5.00K |
| Susquehanna International Group, LLP | 10,995 | $1.81K |
| XTX Topco Ltd | 10,740 | $1.77K |
| UBS Group AG | 7,874 | $1.30K |
| Bank of America Corp | 1,621 | $266 |